Zurcher Kantonalbank Zurich Cantonalbank Purchases 3,228 Shares of Natera, Inc. (NASDAQ:NTRA)

Zurcher Kantonalbank Zurich Cantonalbank raised its position in Natera, Inc. (NASDAQ:NTRA) by 15.7% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 23,844 shares of the medical research company’s stock after purchasing an additional 3,228 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Natera were worth $1,494,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of NTRA. CWM LLC increased its stake in Natera by 224.4% in the third quarter. CWM LLC now owns 1,317 shares of the medical research company’s stock valued at $58,000 after purchasing an additional 911 shares in the last quarter. Ellsworth Advisors LLC bought a new stake in shares of Natera during the third quarter worth $364,000. Xponance Inc. increased its position in shares of Natera by 1.8% during the third quarter. Xponance Inc. now owns 14,506 shares of the medical research company’s stock worth $642,000 after acquiring an additional 261 shares in the last quarter. Brown Advisory Inc. increased its position in shares of Natera by 9.2% during the third quarter. Brown Advisory Inc. now owns 4,738 shares of the medical research company’s stock worth $210,000 after acquiring an additional 400 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its position in shares of Natera by 6.7% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 177,159 shares of the medical research company’s stock worth $7,839,000 after acquiring an additional 11,052 shares in the last quarter. Institutional investors own 99.90% of the company’s stock.

Natera Stock Performance

Shares of NTRA stock opened at $91.28 on Friday. The stock has a market cap of $11.02 billion, a P/E ratio of -24.08 and a beta of 1.37. The company has a debt-to-equity ratio of 0.37, a current ratio of 4.10 and a quick ratio of 3.96. The company has a fifty day moving average price of $87.29 and a two-hundred day moving average price of $67.00. Natera, Inc. has a one year low of $36.90 and a one year high of $98.82.

Natera (NASDAQ:NTRA) last announced its quarterly earnings results on Wednesday, February 28th. The medical research company reported ($0.64) EPS for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.09. The firm had revenue of $311.11 million during the quarter, compared to analysts’ expectations of $300.38 million. Natera had a negative net margin of 40.16% and a negative return on equity of 62.19%. As a group, equities analysts predict that Natera, Inc. will post -2.35 EPS for the current year.

Analyst Ratings Changes

Several brokerages have recently issued reports on NTRA. Piper Sandler increased their price objective on shares of Natera from $70.00 to $110.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 6th. Raymond James downgraded shares of Natera from a “strong-buy” rating to an “outperform” rating and increased their price objective for the stock from $68.00 to $85.00 in a research report on Tuesday, February 20th. Sanford C. Bernstein raised shares of Natera from a “market perform” rating to an “outperform” rating and set a $120.00 price objective for the company in a research report on Friday, April 5th. Canaccord Genuity Group increased their price objective on shares of Natera from $87.00 to $100.00 and gave the stock a “buy” rating in a research report on Thursday, February 29th. Finally, The Goldman Sachs Group increased their price objective on shares of Natera from $90.00 to $100.00 and gave the stock a “buy” rating in a research report on Monday, April 15th. One equities research analyst has rated the stock with a sell rating and fourteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $86.40.

Insider Buying and Selling at Natera

In other news, insider Daniel Rabinowitz sold 35,307 shares of the firm’s stock in a transaction dated Tuesday, February 27th. The shares were sold at an average price of $75.09, for a total transaction of $2,651,202.63. Following the completion of the sale, the insider now owns 204,218 shares in the company, valued at approximately $15,334,729.62. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other news, CEO Steven Leonard Chapman sold 6,816 shares of the firm’s stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $93.13, for a total transaction of $634,774.08. Following the completion of the sale, the chief executive officer now owns 227,710 shares in the company, valued at approximately $21,206,632.30. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Daniel Rabinowitz sold 35,307 shares of the firm’s stock in a transaction dated Tuesday, February 27th. The stock was sold at an average price of $75.09, for a total transaction of $2,651,202.63. Following the sale, the insider now owns 204,218 shares of the company’s stock, valued at approximately $15,334,729.62. The disclosure for this sale can be found here. Insiders sold a total of 453,644 shares of company stock worth $36,594,940 over the last quarter. 9.42% of the stock is currently owned by insiders.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.